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Available online 19 May 2019complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemother-
apy (NACT). Our aimwas to review current evidence to determinewhether the CRS is prognostic inwomenwith
tubo-ovarian HGSC treated with NACT.
Methods.We established an international collaboration to conduct a systematic review and meta-anal-
ysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3–4
NACT cycles and N6-months follow-up. Random effects models were used to derive combined odds ratios
in the pooled population to investigate associations between CRS and progression free and overall survival
(PFS and OS).
Results. 877 patients were included from published and unpublished studies. Median PFS and OS were
15 months (IQR 5–65) and 28 months (IQR 7–92) respectively. CRS3 was seen in 249 patients (28%). The
pooled hazard ratios (HR) for PFS and OS for CRS3 versus CRS1/CRS2 were 0·55 (95% CI, 0·45–0·66; P b
0·001) and 0·65 (95% CI 0·50–0·85, P = 0·002) respectively; no heterogeneity was identiﬁed (PFS: Q
= 6·42, P = 0·698, I2 = 0·0%; OS: Q = 6·89, P = 0·648, I2 = 0·0%). CRS was signiﬁcantly associated
with PFS and OS in multivariate models adjusting for age and stage. Of 306 patients with known germline
BRCA1/2 status, those with BRCA1/2 mutations (n = 80) were more likely to achieve CRS3 (P = 0·027).
Conclusions. CRS3 was signiﬁcantly associated with improved PFS and OS compared to CRS1/2. This val-
idation of CRS in a real-world setting demonstrates it to be a robust and reproducible biomarker with poten-
tial to be incorporated into therapeutic decision-making and clinical trial design.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
H I G H L I G H T S
• The Chemotherapy response score (CRS) assesses histological effect in ovarian cancer after neoadjuvant che-
motherapy (NACT).
• The CRS is associated with progression-free and overall survival.
• CRS could provide useful information to estimate a patient's probability of early vs. late relapse.
• The CRS is an appealing primary endpoint in clinical trials as a surrogate for survival as it can bemeasured ear-
lier.
• We recommend the CRS be incorporated as an endpoint in clinical trials of novel therapeutic agents that have a
NACT arm.Keywords:
Neoadjuvant chemotherapy
Chemotherapy response score
Prognosis
High-grade serous tubo-ovarian cancerContents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 442
2. Material and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 443
3. Search strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 443
4. Inclusion and exclusion criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 443
5. Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 443
6. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 443
7. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 445
Conﬂict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447
Funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447
Availability of data and material . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447
Authors' contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447
Appendix A. Supplementary data. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4481. Introduction
Neoadjuvant chemotherapy (NACT) is increasingly used to treat
women with tubo-ovarian high-grade serous carcinoma (HGSC) fol-
lowing the results of two randomized trials that demonstrated non-
inferior overall survival (OS), and lower morbidity and mortality,
compared to primary surgery in advanced disease [1,2]. Interval
debulking surgery (IDS) following NACT provides an opportunity to
assess tumor response to antineoplastic treatments. Validated scor-
ing systems provide prognostic information in patients with breast,
esophageal, gastric and rectal cancers following neoadjuvant treat-
ment, and are used to guide treatment decisions after surgery [3–
6]. In 2015, a standardized scoring system for histological tumor re-
gression in tubo-ovarian HGSC was proposed by Böhm and col-
leagues, who developed and validated a three-tier chemotherapy
response score (CRS) that stratiﬁes patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response
based on omental examination [7]. Importantly, the CRS has been
shown to be reproducible amongst pathologists [8]. The Interna-
tional Collaboration on Cancer Reporting (ICCR) subsequently rec-
ommended the use of the CRS to assess histological NACT effect in
HGSC to enable standardized and objective reporting [9]. Single in-
stitution retrospective studies have since reported an association be-
tween CRS and progression-free survival (PFS) but not OS [10–13].
These studies are limited by small sample sizes, lack of power to de-
tect associations between CRS and OS, heterogeneity in participants,
and the number of NACT cycles and regimens used. In recognition of
the precedent of insufﬁciently validated diagnostic tools that have
previously been implemented in clinical trials prematurely [14] we
formed an international collaborative network to analyse pooled ret-
rospective patient level data from several centers. This collaboration
enabled meta-analysis of individual patient data (IPD) with
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power to investigate the prognostic role of the CRS, with the goal of
providing a sufﬁcient level of validation that may permit use of the
CRS in clinical trials.
Our primary aim was to determine whether the CRS was prognostic
in women with tubo-ovarian HGSC treated with NACT. Secondary ob-
jectives were to investigate whether i) the CRS correlated with macro-
scopic residual disease at completion of interval surgery, ii) the CRS
predicted platinum-resistance (as conventionally deﬁned by disease
progression b6 months following last adjuvant chemotherapy cycle
[15]), iii) a biochemical response in serum CA125 from diagnosis to
pre-interval surgery was prognostic, and iv) patients with CRS3 had a
higher frequency of pathogenic germline BRCA1/2mutations compared
to those with CRS1 and CRS2.
2. Material and methods
We performed a systematic review andmeta-analysis based upon a
Medline and PubMed search from August 31, 2015 to June 30, 2018,
with no language restrictions. This review was conducted following
the Preferred Reporting Items for Systematic Reviews and Meta-Analy-
ses (PRISMA).
Ethical approval was obtained (St John of God Healthcare Human
Research Ethics Committee Reference 1291) for transfer of de-identiﬁed
individual patient data from participating sites for statistical analysis at
the Institute for Health Research, University of Notre Dame, in Freman-
tle, Western Australia. Principal investigators at individual study sites
obtained country-speciﬁc and local approvals.
3. Search strategy
We used the search terms “chemotherapy response score” AND
“high-grade serous ovarian carcinoma”. Amulti-center research consor-
tium that included 16 sites to access IPD from published and unpub-
lished studies supplemented the search.
Published studies that reported the use of the CRS in patients with
stage IIIC or IV ovarian, fallopian tube, or primary peritoneal HGSC,
treated by NACT and IDS, were eligible for inclusion. After removing du-
plicates, two authors (PC and AP) independently examined titles and
then abstracts of all studies identiﬁed according to the search strategy.
The full texts of relevant abstracts were retrieved for further assess-
ment. Uncertainties were resolved through discussion with a third au-
thor (NS). The Newcastle-Ottawa Scale and elements from the
Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) quality assessment tool were used to assess risk of bias,
with a low risk of bias considered a score of ≥7 or more [16,17].
Unpublished data were obtained from investigators who had previ-
ously published studies on prognostic importance of histological ﬁnd-
ings other than CRS [18–20], had presented data on CRS at
international conferences, were known by the authors (NS, CBG, PC)
to be from academic/tertiary referral centers and to be using CRS rou-
tinely in their clinical practice (NZ, NL, Canada, UK) and/or had
expressed interest in contributing data to the meta-analysis through
retrospective review and scoring of consecutive eligible cases from
their centers (UK).
4. Inclusion and exclusion criteria
Study eligibility criteria were: patients with histologically conﬁrmed
International Federation of Gynecology and Obstetrics (FIGO) 2014
stage IIIC or IV ovarian, fallopian tube, or primary peritoneal HGSC,
who had received 3–4 cycles of platinum-based NACT prior to IDS and
had a minimum of 6months follow up information. An additional crite-
rion is implicit in the scoring system,which utilizes the extent of disease
in the single omental section showing the worst response to NACT, i.e.
the maximum tumor load present; this is only valid in cases withdocumented omental disease prior to NACT. A standardized data collec-
tion tool was developed and disseminated to collect the following vari-
ables; age at diagnosis, date of ﬁrst NACT cycle, date of last adjuvant
chemotherapy cycle, serum CA125 values prior to the ﬁrst NACT cycle
and before IDS, number of NACT cycles administered, FIGO stage, resid-
ual disease (surgeon's visual assessment of completeness of the IDS cat-
egorized as no macroscopic residual disease ‘R0’, ≤1 cm and N1 cm),
germline BRCA1/BRCA2mutation status, and date of disease progression,
death or last known follow up. Clinical and laboratory data were col-
lected through chart and tissue repository database review. Any dis-
crepancies were resolved by consensus and arbitration by a panel of
investigators (NS, PC, AP, SB, BG, MB, CS and TM).
Tumor regression scores were assigned by local gynecological pa-
thologists at participating sites based on the omental section showing
the least NACT response, as detailed in the original publication describ-
ing the CRS score (Supplementary Table 1). The original publication ad-
vised that CRS3 cases should be sub-divided into those with no residual
tumor in the omentum and thosewith presence of residualmicroscopic
omental tumor (Supplementary Table 1) at time of IDS.
5. Statistical analysis
Statistical analysis was performed using Stata 15.0 (Stata Statistical
Software Release 15; StataCorp LP, College Station, TX). Statistical signif-
icance was determined as a P value b0·05 for all hypothesis tests. Ran-
dom IPDmeta-analysismethodswere used to assess PFS andOS.Hazard
ratios (HR), odds ratios (OR) and their 95% conﬁdence intervals (CI)
were calculated and reported. Tests for heterogeneity were conducted
and the I2 statistic was calculated to quantify the degree of heterogene-
ity between sites. Time-to-event analysis was performed using Cox pro-
portional hazard regression models to investigate factors associated
with PFS and OS. PFS was deﬁned as the date of the ﬁrst NACT cycle to
disease progression, as per the Gynecologic Cancer Intergroup CA125
criteria [15] or radiological progression or death, whichever occurred
ﬁrst. OS was deﬁned as the date of ﬁrst NACT cycle to date of death or
date of last known follow-up. In the presence of non-proportional haz-
ards, a parametricWeibull regressionmodel was used. Evidence of non-
proportionality was assessed using PHTEST at the 5% level. PFS and OS
for CRS3 were compared to CRS1/CRS2 combined7. Variables included
in the models were age at diagnosis (years), disease stage, and com-
pleteness of IDS. The CA125 response and germline BRCA1/2mutation
status were included in subsequent models. Violation of the propor-
tional hazard assumption for the Cox model was tested using
Schoenfeld residuals. The Harrell's C statistic was used to measure the
performance of the survival models in discriminating overall PFS and
OS to quantify the value of CA125 reduction (from baseline to pre-
IDS) when assessed with clinicopathological factors.
Chi-square and Fisher exact testswere used to examine groupdiffer-
ences between CRS and other categorical clinical variables. A multivari-
ate logistic regression was performed to investigate the prognostic
signiﬁcance of CRS with surgical residual disease, platinum resistance,
deﬁned as disease progression b6 months after the last chemotherapy
cycle, and germline BRCA1/2mutation status.
6. Results
We retrieved 6 published papers and 5 met the inclusion criteria
[7,10–13]. 1 duplicate was removed (Fig. 1). Risk of bias assessment is
shown in Supplementary Table 2. Data were available for 1365 patients
from 11 countries (Fig. 1 and Supplementary Table 3). After exclusion of
488 patients who did not meet inclusion criteria, the ﬁnal cohort com-
prised 877 patients (Fig. 1). Patient characteristics, details of NACT and
clinicopathological outcomes are presented in Table 1 and Supplemen-
tary Table 3. Of the sites thatwere able to provide complete data for CRS
3 cases (n= 202) information was available regarding anatomical site/
presence of residual viable tumor after IDS for 100 cases; these were
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these 32 (32%)were CRS 3with no residual tumor in the omentum; no-
tably only 11 of these cases (11/411; 2.7%) showed a complete patho-
logical response (i.e. no residual tumor at any site based on
histopathological assessment), as the remainder showed residual dis-
ease at sites other than the omentum. Frequencies of the CRSs reported
by each country varied signiﬁcantly (P b 0·001).
677 of 877 (77·2%) patients developed recurrent disease. Median
PFS was 14·9 months (IQR 5.4–65.2; Supplementary Table 3). The
pooled hazard ratio (HR) for PFS (CRS3 compared to CRS1/CRS2) was
0·55 (95%CI, 0·45–0·66; P b 0·001; Fig. 2). No heterogeneity (statistical
difference in reporting of CRS and PFS between countries) was identi-
ﬁed (Q = 6·42, P = 0·698, I2 = 0·0%). In a Cox model adjusting for
age, stage and residual disease at IDS, CRS and residual diseasewere sig-
niﬁcantly associated with PFS. CRS1/2 combined were signiﬁcantly as-
sociated with worse PFS compared to CRS3 (HR, 1·90; 95%CI, 1·58–
2·28; P b 0·001; Table 2). Patients with any residual disease were at in-
creased risk of progression independent of CRS scores (Table 2, Supple-
mentary Fig. 1). A sub-group analysis of patients with CRS3 showed the
presence of residual disease in the omentum vs. no residual omental
disease to be associated with an increased risk of progression (HR,
1·94; 95%CI, 1·34–2·80; P b 0·001; Supplementary Table 4, Supple-
mentary Figs. 3 and 4).
There were 407 deaths. The pooled HR for OS (CRS3 compared to
CRS1/CRS2) was 0·65 (95%CI 0·50–0·85, P = 0·002; Fig. 2). NoFig. 1. Study sheterogeneity was identiﬁed (Q = 6·89, P = 0·648, I2 = 0·0%). In a
multivariate survival model that compared CRS3 with CRS1 and CRS2
combined, CRS1/2 were associated with signiﬁcantly worse OS (HR,
1·73; 95%CI, 1·35–2·25; P b 0·001; Table 2). Older age at diagnosis (P
= 0·032) and residual disease at completion of IDS (N0 cm and ≤1 cm
v R0; HR, 1·49; 95% CI, 1·19–1·85; P b 0·001; N1 cm vs. R0; HR, 2.30;
95% CI, 1·71–3·08, P b 0.001) were associated with worse OS (Table 3,
Supplementary Fig. 2). A sub-group analysis of patients with CRS3,
showed the presence of residual disease in the omentum vs. no residual
omental disease to be associatedwithworse OS (HR, 2·25; 95%CI, 1·31–
3·87; P= 0·003; Supplementary Table 4, Supplementary Figs. 3 and 4).
Because residual disease has consistently been shown to be themost
important prognostic factor inwomenwith tubo-ovarianHGSC,we per-
formed a subgroup analysis of the 508 women debulked to R0 (Supple-
mentary Table 5). In this group of patients CRS was signiﬁcantly
associated with PFS (CRS1/CRS2 vs. CRS3: HR, 1·81; 95%CI, 1·43–
2·29; P b 0·001; Supplementary Table 6) and OS (CRS1/CRS2 vs.
CRS3:HR, 1·50; 95%CI, 1·08–2·09; P=0·017; Supplementary Table 6).
Data on CA125 response to NACT were available for 809 patients.
Median pre-treatment levels were 1073 kU/L (range, 4–52,785 kU/L).
Overall, 7 (1.0%) patients did not show any reduction in their CA125
values from baseline to pre-IDS (4 had CRS1, 2 had CRS2 and 1 had
CRS3). Two patients had CA125 values within the normal range at the
start of treatment that did not alter (1 had CRS2 and 1 had CRS3).
There were 774 patients who had a CA125 reduction of ≥50% and 565election.
Table 1
Patient baseline characteristics, histological scoring of tissue, and surgical outcome at in-
terval debulking surgery.
Characteristic No. (N =
877)
Percentage
%
Median age, years (range) 62
(30–88)
FIGO stage
IIIC 544 62.0
IV 333 38·0
Cycles of neoadjuvant chemotherapy
Three 572 65·2
Four 305 34·8
Regimen of initial neoadjuvant chemotherapy
Carboplatin + Paciltaxel 698 79·6
Carboplatin monotherapy 53 6·0
Othera 58 6·6
Unknown 68 7·8
Outcome of debulking surgery – residual disease (cm)
0 (R0) 508 57·9
N0 but ≤1 269 30·7
N1 84 9·6
vUnknown 16 1·8
CRS assigned
Score 1 135 15·4
Score 2 493 56·2
Score 3 249 28·4
Germline BRCA mutation status
No pathogenic BRCAmutation 226 25·8
BRCA1/2mutation detected 80 9·1
Unknown 571 65·1
Abbreviations: BRCA, breast cancer susceptibility gene; CRS, chemotherapy response
score; FIGO, International Federation of Gynecology Obstetrics; R0, no residual disease.
a Other included: Carboplatin+Paciltaxel+Bevacizumab, Carboplatin+Gemcitabine
or Carboplatin + Bevacizumab.
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levels. CA125 response was not found to be a reliable prognostic factor
for PFS (Harrell's C = 0·6092) or OS (Harrell's C = 0·6257) (Supple-
mentary Table 7) and did not predict residual disease at completion of
IDS (HR, 0·93; 95%CI, 0·69–1·29; P = 0·696).
80 patients had a germline BRCA1/2 mutation (8 had CRS1, 39 had
CRS2 and33 had CRS3). 226patients had nogermlineBRCA1/2mutation
and BRCA status was unknown in 571 patients. Patients with BRCA1/2
mutations were more likely to have a CRS3 compared to those who
were BRCA1/2wild type (P= 0·027) andwere less likely to have recur-
rence (P=0.025, Supplementary Table 8) or to be deceased (P=0.036,
Supplementary Table 8).
The outcomes for residual disease at IDS by study are presented by
CRS in Supplementary Table 5 (P b 0·001). Complete resection (R0)
was achieved in 72·6% of patients (178 of 245) with CRS3 and 53·6%
(330 of 616) patients with CRS1/CRS2 combined (P b 0·001; Supple-
mentary Table 5). In a logistic regression model that adjusted for age,
FIGO stage and CRS, residual disease was signiﬁcantly more likely in pa-
tients with CRS1/CRS2 compared to those with CRS3 (HR, 2·36; 95%CI,
1·70–3·27; P b 0·001).
206 patients recurred in the platinum-resistant timeframe; 85·4%
had CRS1/CRS2 and 14·6% had CRS3 (P b 0·001, Supplementary Table
9). A multivariate logistic regression model showed the likelihood of
platinum-resistance was signiﬁcantly higher in patients with CRS1/
CRS2 compared with those with CRS3 (HR, 2·62; 95%CI, 1·62–4·22; P
b 0·001) and for those with residual disease N1 cm (HR, 1·82; 95%CI,
1·05–3.16; P = 0·033).
7. Discussion
This study showed that CRS was signiﬁcantly associated with PFS
and OS in multivariate analyses that adjusted for established ovarian
cancer prognostic factors. Consistent with these ﬁndings, the CRS pre-
dicted surgical residual disease, platinum resistance, and germline
BRCA1/2mutation status, which are all independently associated with
survival. Despite the limitations of this study, discussed below, this is a
real-world demonstration of the applicability and performance of CRS
in routine clinical practice, outside the conﬁnes of a highly controlled
clinical trial setting.
In terms of its prognostic signiﬁcance the CRS system is a three tier
score, with CRS3 characterizing a patient cohort with favourable out-
comes. Analysis of CRS3 by absence of residual omental disease vs. pres-
ence of residual microscopic omental disease suggests that CRS3
separates into two prognostic sub-groups with the former being associ-
ated with improved PFS and OS as compared to the latter. Notably CRS3
with no residual disease in the omentum does not equate to what is
generally considered a complete pathological response, i.e. no residual
tumor at any site; only 11/32 (34%) of cases with no residual tumor in
the omentum showed absence of tumor at all other sites. The differ-
ences observed for PFS and OS between CRS1 and CRS2 were not statis-
tically signiﬁcant. The subdivisions of both CRS3 and this less favourable
prognostic group of CRS1/CRS2 using more objective parameters than
morphology alone, including genomics and assessment of immune cell
inﬁltration, should be the subject of future studies.
Comparison of CRS scores between countries also demonstrates var-
iability between proportions of cases showing CRS1/CRS2 versus CRS3.
A previous study on reproducibility of CRS assignment between pathol-
ogists from different centers, and with different levels of experience,
showed that training using the online tool and the original paper were
sufﬁcient to produce reproducible scoring of the same histological sec-
tions, with exceptionally high agreement in cases scored as CRS3
(kappa value 0.926) [7,8]. For this reason, we believe it is unlikely that
the difference in proportion of CRS3 cases is related to interobserver
variation in scoring.We chose not to include central review of cases be-
cause of the previous demonstration of reproducibility [8] and because
our aim was to determine how well CRS performs as a prognosticbiomarker in different centers worldwide as used by local pathologists,
rather than with the incorporation of any centralized arbitration. The
similarity in outcome prediction for CRS1/CRS2 vs. CRS3 across coun-
tries suggests that the scoring system is being applied as devised. A pos-
sible explanation for the observed difference between countries is
variation in case selection at two decision points: the decision to offer
NACT as opposed to primary surgery, and subsequently the decision to
carry out IDS after 3–4 NACT cycles. Both are highly dependent on
local surgical oncological practices, which vary widely [1]. Whilst it is
probable that all patients given NACT who showed an excellent radio-
logical and biochemical response would proceed to IDS, there would
be some variation in the proportion of poor responders who would be
offered IDS, based on the subjective assessment of likelihood of achiev-
ing complete or b1 cm resection of all macroscopic disease. Other possi-
ble explanations could be the proportion of cases excluded due to loss to
follow-up, which could diminish the numbers of poor responders, and
variations in chemotherapy schedule and dose intensity.
The CRS was associated with pathogenic germline BRCA1/2 muta-
tions, which validates BRCA1/2mutations as a predictivemarker of plat-
inum response [21,22]. Importantly we observed a signiﬁcant
association between CRS1/CRS2 and disease progression within
6 months. The HGSC cases with CRS3 were enriched for BRCA1/2muta-
tions, and likely for other homologous DNA repair pathway defects, and
we hypothesise that those cases with CRS1/CRS2 will contain a higher
proportion of CCNE1-ampliﬁed tumors of the C1mesenchymal subtype,
and characterized by fold-back inversions and other molecular markers
of poor prognosis [23]. This would require conﬁrmation in large pro-
spective studies but suggests that CRS could be used to identify patients
who might beneﬁt from alternative therapeutic strategies.
It is notable that in the current meta-analysis CA125 response did
not predict survival, CRS or surgical residual disease in patients who
showed a sufﬁcient response to NACT to undergo IDS.
Our study has several limitations that should be acknowledged. All
included studies were retrospective cohorts and our multivariate
446 P.A. Cohen et al. / Gynecologic Oncology 154 (2019) 441–448analysis did not adjust for patient comorbidities and performance sta-
tus. We did not monitor patient selection from contributing centers
and this could have resulted in selection bias. There was no central pa-
thology review and it is conceivable that subjective interpretation led
to reported CRS values that might have misclassiﬁed some cases. Resid-
ual disease at IDS relied upon the surgeon's report, which is notoriously
unreliable andmayhave biased ourﬁndings [24]. Time from completion
of NACT to initiation of post-operative adjuvant treatment has recentlya) PFS adjusted Forest plot.
b) OS adjusted Forest plot.
Fig. 2.Hazard ratio plots by country for a) PFS andB)OS adjusted for patient age at diagnosis, dis
participating sites and corresponding horizontal line is the 95% conﬁdence interval (CI). The area
line and centre of the blue diamond is overall pooled HR and the horizontal tip of the diamondbeen shown to inﬂuence survival [25]; we did not collect this informa-
tion, and it is possible that variation in this time interval introduced bias.
It is acknowledged that many factors contribute to the timing and
pattern of disease relapse, such as the frequency of diagnostic proce-
dures and follow-up intervals, diagnosticmethods and tools used, resid-
ual disease volume and location, rate of tumor growth, differences in
therapy and acquired platinum resistance. The evaluation of tumor re-
sponse based only on omental disease does not take into account theease stage and residual disease status. The centre of each square is the hazard ratio (HR) for
of the square is proportional to the number of disease recurrences at each site. The broken
is the 95% CI.
Table 2
Multivariate survival analysis of prognostic factors for PFS andOS (presents CRS 1 and 2 vs.
3) adjusted for patient age at diagnosis, disease stage, residual disease status and CRS.
Factors Progression free survival Overall survival
HR 95% CI P HR 95% CI P
Age (years) 1·00 1·00–1·01 0·494 1·01 1·00–1·02 0·032
FIGO stage
IIIC 1·00 – – 1·00 – –
IV 1·08 0·92–1·26 0·336 1·15 0·94–1·41 0·182
Outcome of debulking
surgery at IDS,
residual disease (cm)
0 (R0) 1·00 – – 1·00 – –
N0 and ≤1 1·35 1·14–1·60 0·001 1·49 1·19–1·85 b0·001
N1 1·61 1·25–2·06 b0·001 2·30 1·71–3·08 b0·001
Unknown 1·12 0·64–1·95 0·685 1·15 0·59–2·25 0·682
CRS
Score 1 & 2 1·90 1·58–2·28 b0·001 1·73 1·35–2·22 b0·001
Score 3 1·00 – – 1·00 – –
Abbreviations: CI, conﬁdence interval; CRS, chemotherapy response score; FIGO, Interna-
tional Federation of Gynecology Obstetrics; HR, hazard ratio; R0, no residual disease. Test
of proportional-hazards assumption for PFS, P = 0·6044 and OS, P = 0·4193.
447P.A. Cohen et al. / Gynecologic Oncology 154 (2019) 441–448possible impact of tumor heterogeneity. These differences notwith-
standing, the CRS provides an objective measure and biological readout
of the response to NACT, which appears to encapsulate all of the afore-
mentioned parameters and their complex interplay.
Strengths of our study are the large sample that included IPD from
16 centres in 11 countries and a meta-analysis that utilized published
and unpublished studies with minimal heterogeneity. The main
strength of this study is the demonstration of a strong and plausible as-
sociation of CRS with NACT outcome and survival in a real-world, het-
erogeneous study population.
A Society of Gynecologic Oncology White Paper on an FDA Ovarian
Cancer Clinical Trial Endpoints Workshop held in 2015 highlighted the
potential of NACT response to act as a platform for biomarker discovery
and regulatory approval of novel therapies [26]. However, despite
strong support it was felt further work was required. The White Paper
highlighted unanswered questions that included the true prevalence
of complete pathological response in patients treated by NACT, and
whether pathological response should be a surrogate for PFS and/or
OS. The current study provides provisional answers to these questions:
the prevalence of CRS3 in 877 women treated by NACTwhowent on to
IDS was 28% and CRS would appear to be a surrogate for both PFS and
OS, independent of other known prognostic factors. In the publication
by Böhm and colleagues that described and validated the CRS,Table 3
Multivariate survival analysis of prognostic factors for PFS (presents CRS 1, 2 and 3) ad-
justed for patient age at diagnosis, disease stage, residual disease status and CRS.
Factors Progression free survival Overall survival
HR 95% CI P HR 95% CI P
Age (years) 1·00 1·00–1·01 0·502 1·01 1·00–1·02 0·030
FIGO stage
IIIC 1·00 – – 1·00 – –
IV 1·10 0·94–1·29 0·230 1·18 0·96–1·45 0·126
Outcome of debulking
surgery at IDS,
residual disease (cm)
0 (R0) 1·00 – – 1·00 – –
N0 and ≤1 1·36 1·14–1·61 b0·001 1·48 1·19–1·85 b0·001
N1 1·53 1·19–1·97 0·001 2·18 1·62–2·95 b0·001
Unknown 1·14 0·66–1·99 0·638 1·16 0·59–2·27 0·667
CRS
Score 1 2·28 1·78–2·92 b0·001 2·09 1·50–2·89 b0·001
Score 2 1·82 1·51–2·20 b0·001 1·66 1·28–2·14 b0·001
Score 3 1·00 – – 1·00 – –
Abbreviations: CI, conﬁdence interval; CRS, chemotherapy response score; FIGO, Interna-
tional Federation of Gynecology Obstetrics; HR, hazard ratio; R0, no residual disease. Test
of proportional-hazards assumption for PFS, P = 0·4316 and OS, P = 0·4267.histological regression in the primary adnexal tumor did not stratify pa-
tients into prognostic groups and adnexal response scores showed infe-
rior reproducibility; in contrast, omental scores were prognostic and
reproducible [7]. In the current study we were not able to assess histo-
logical regression in the adnexa or at other metastatic sites in all pa-
tients, and so it is uncertain whether our ﬁndings translate to all
tissues and compartments such as visceral and diaphragmatic metasta-
ses, or retroperitoneal lymph nodes. Our results do however show that a
complete or near complete pathological response in omental tumor
alone (CRS3) is a biomarker for survival.
Our ﬁndings require prospective validation. However, based on our
results we recommend that the CRS be incorporated as an endpoint in
clinical trials of novel therapeutic agents that have a NACT arm, and
that CRS3 continue to be further classiﬁed with respect to the presence
or absence ofmicroscopic residual disease in the omentum. If conﬁrmed
in prospective studies, the CRS represents an appealing primary end-
point in clinical trials as a surrogate for survival because it can be
measured earlier. Of note, the CRS is the primary endpoint in iPRIME,
an ongoing phase II study of Durvalumab plus Tremelimumab in combi-
nation with NACT in newly diagnosed women with HGSC
(ACTRN12618000109202). Furthermore, the CRS offers an opportunity
to personalize treatment and may transform future clinical trial design,
by stratifying treatment according to CRS following IDS. Future research
should focus on the development of a statistical model to predict prog-
nosis that incorporates the CRS with radiological and biochemical re-
sponse, surgical outcome, tumor immune proﬁle and molecular
classiﬁcation.
The CRS could provide clinically useful information to estimate a
patient's probability of early vs. late relapse. Most of the patients who
will not relapse at ﬁve years show CRS3, making these women with
no or minimal residual disease an attractive group for an additional ad-
juvant therapeutic agent such as poly (adenosine diphosphate–ribose)
polymerase (PARP) inhibitors, that prolong PFS and could result in
more cures, as shown in the recently published SOLO1 trial of mainte-
nance Olaparib in epithelial ovarian cancer patientswith BRCA1/2muta-
tions [27]. In contrast, patients whose tumors are found to have CRS1/2
will likely experience recurrence within 5 years; given this poor prog-
nosis these patients could enter immediately into trials of new therapy.
In summary, in this IPD meta-analysis of 877 patients, the CRS was
signiﬁcantly associated with PFS and OS in women with tubo-ovarian
HGSC treated by NACT. This biomarker is now sufﬁciently validated
that it can be incorporated into prospective clinical trial design to assess
its potential to guide therapeutic decision-making.
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